Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors

NCT02363933 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT02363933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02363933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors
Lead sponsor
Duke University
Phase
Phase 4
Overall status
Completed
Start date
April 7, 2015
Completion date
April 10, 2017
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, primary